Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Microfat + platelet-rich plasma (MF-PRP) is a combination therapy that utilizes two autologous components: microfat (MF) derived from adipose tissue and platelet-rich plasma (PRP) obtained from blood. This biotherapy combines the structural support and regenerative properties of adipose-derived stem cells (ADSCs) from microfat with the growth factors and anti-inflammatory properties of PRP. The treatment involves harvesting adipose tissue through minimally invasive liposuction, processing it to obtain microfat, and combining it with PRP prepared from the patient's blood. This combination is then injected into the target area, typically joints affected by osteoarthritis or other degenerative conditions. The therapy aims to reduce inflammation, provide cushioning, and potentially stimulate tissue regeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microfat + platelet-rich plasma.